Wednesday, October 29, 2014 5:44:44 PM
The effect of p53 has to be localized for efficient tumor cell suppression. Big pharma a decade or so ago tried flushing cancer patients with the p53 protein but it quickly became to toxic without much in the way of tumor suppression the attempt here is to get the individual cells to produce p53. I mention this Just in case Kevetrin is simulating p53 itself.
The FDA's definition of Gene therapy: Gene therapy is a medical intervention based on modification of the genetic material of living cells.
Genetic material: The genetic material of a cell or an organism refers to those materials found in the nucleus, mitochondria and cytoplasm, which play a fundamental role in determining the structure and nature of cell substances, and capable of self-propagating and variation.
The TP53 gene, the MDM2 pathway and p53 protein are in the nucleus, through the nuclear envelope and in to the cytoplasm.
I don't care to nit-pick about what Gene therapy is...but I would caution you about announcing that you know the method of action (MOA) of Kevetrin. I am not even sure Dr. Menon knows all those details yet.
Kevetrin doesn't really activate the TP53 gene, rather the gene product p53 (protein of 53 kDa size), via multiple mechanisms. We are not modifying any genes.
Gene therapy would be, as you said, insertion or knockout of genes, or modification of (mutated) genes. Human clinical trials for gene therapy have to go through additional precautions, such as staggered starts, the recombinant DNA advisory committee, and other.
http://osp.od.nih.gov/office-biotechnology-activities/biomedical-technology-assessment/hgt/rac
Gene therapy companies include: SGMO, BLUE, KITE, etc... but not CTIX. Here is a list of all the Gene Therapy trials that have occurred in the US:
http://osp.od.nih.gov/sites/default/files/resources/PROTOCOL_0.pdf
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
FEATURED CBD Life Sciences, Inc. (CBDL) Reaches Unprecedented Heights With Explosive Growth and Strategic Expansion in 2024 • Oct 8, 2024 8:00 AM
BNCM COMPLETES MERGER WITH DELEX HEALTHCARE • BNCM • Oct 8, 2024 9:54 AM
Unitronix Corp. to Invest $3 Million in USA Unity Coin Project • UTRX • Oct 7, 2024 7:08 AM
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM